HC Wainwright set a $3.00 target price on EyeGate Pharma (NASDAQ:EYEG) in a research note published on Sunday, March 11th. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.
Separately, ValuEngine raised EyeGate Pharma from a strong sell rating to a sell rating in a research report on Friday, February 2nd.
EyeGate Pharma stock traded up $0.03 during trading on Friday, hitting $0.39. 280,619 shares of the company were exchanged, compared to its average volume of 310,016. EyeGate Pharma has a 52 week low of $0.33 and a 52 week high of $2.43. The company has a market capitalization of $6.30, a P/E ratio of -0.38 and a beta of 3.58.
A hedge fund recently raised its stake in EyeGate Pharma stock. Vanguard Group Inc. grew its position in shares of EyeGate Pharma (NASDAQ:EYEG) by 0.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 247,319 shares of the specialty pharmaceutical company’s stock after buying an additional 1,988 shares during the period. Vanguard Group Inc. owned 2.27% of EyeGate Pharma worth $339,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.48% of the company’s stock.
About EyeGate Pharma
EyeGate Pharma is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its products include EGP-437 and EyeGate II Delivery System. EGP-437 treat non-infectious anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris or ciliary body.
Receive News & Ratings for EyeGate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EyeGate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.